EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about ...

XB-010 is under clinical development by Exelixis and currently in Phase I for Triple-Negative Breast Cancer (TNBC).

Cabometyx is under clinical development by Exelixis and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase II drugs for Salivary Gland Cancer have a 14% phase transition ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $33.94 which represents a slight increase of $0.64 or 1.92% from the prior close of $33.3. The stock opened at $33.54 and touched a low ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

Mid-cap Health Care company Exelixis has logged a -1.2% change today on a trading volume of 1,601,263. The average volume for ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps an Outperform rating on the shares. Zanzalintinib ...

Geron Corporation (NASDAQ:GERN) has a negative Return on Invested Capital (ROIC) of -68.21%, indicating challenges in ...

The global phosphoinositide 3-kinase inhibitor market is poised to witness significant growth, projected to expand at a robust CAGR of 5.61% during the forecast period from 2019 to 2026.

Alameda, CA-based Exelixis, Inc. is an oncology-focused biotechnology company that primarily focuses on the discovery, development and commercialization of new drugs for the treatment of ...

Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...

Brookline Capital Markets analysts initiated coverage on Exelixis (NASDAQ:EXEL) with a Buy rating and a $40 price target, ...